A new viral transport medium that enables collection and rapid inactivation of the SARS-CoV-2 virus, and stabilizes viral RNA at ambient temperature for transportation and use in in vitro diagnostic testing procedures, is now available in Europe.

Moderna and Thermo Fisher Scientific Inc.announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.

According to Radio Television Hong Kong and Sing Tao Daily reports on February 20, a study found that the new coronavirus may cause hypogonadism and decreased fertility in male patients, and patients will still be affected after recovery.

Roche announced on Wednesday that it received CE marking for two of its SARS-CoV-2 tests to run on the firm's new Cobas 5800 system.

Traces of the SARS-CoV-2 coronavirus that causes COVID-19 can be detected in microscopically small fluid droplets exhaled during a very short time span. This is the finding of a new study from the University of Gothenburg.

On the evening of February 18, Shenzhen YHLO Biotech Co., Ltd. announced that it received a purchase order from the Institute of Medical Biology Co., Ltd.. According to the purchase order, MBL will purchase antigen test kits from the YHLO, the total amount is approximately CNY 316 million.

British testing firm DnaNudge announced on Wednesday that it has partnered with Pantonic Health to launch its CovidNudge test in Australia.

Diagnostics manufacturer Quidel reported after the close of the market on Thursday that its fourth quarter revenues fell more than 21 percent year over year due primarily to shift in product mix and decreased COVID-19 product sales.

Recently, Hong Kong has been hit by the epidemic continuously. On February 16, Kang Keren, senior vice president of Wondfo Biotech, said that in response to the epidemic in Hong Kong, Wondfo's "Anti-epidemic pioneer" is preparing to go to the front line and guarantee supply.

Hologic reported after the close of the market on Wednesday that revenues for its first quarter of fiscal year 2022 decreased 9 percent year over year, driven by lower sales of COVID-19 assays.